| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.8 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.8 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |